Citations

Clear

1011 citation(s) found for "Barry, WT".

Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort
Fudim, Marat , Fail, Peter , Shaburishvili, Tamaz, Hummel, Scott L. , Mohan, Rajeev , Mitter, Sumeet S. , Klein, Liviu , Rocha‐Singh, Krishna J. , Patel, Manesh R. , Hummel, Scott L , Litwin, Sheldon E. , Goyal, Parag , Borlaug, Barry A. , Patel, Ravi B. , Reddy, Vivek Y. , Burkhoff, Daniel , Shah, Sanjiv J

Mayo Clinic

European Journal of Heart Failure | May 22, 2022 | Volume: 24 | Issue: 8 | Pages: 1410-1414

10.1002/ejhf.2559 | PMID 35598154 Get It

Aims In heart failure (HF) with preserved ejection fraction (HFpEF), excessive redistribution of blood volume into the central circulation leads to elevations of intracardiac pressures with exercise limitations. Splanchnic ablation for volume management (SAVM) has been proposed as a therapeutic intervention. Here we present preliminary safety and efficacy data from the initial roll‐in cohort of the REBALANCE‐HF trial. Methods and results The open‐label (roll‐in) arm of REBALANCE‐HF will enrol up to 30 patients, followed by the randomized, sham‐controlled portion of the trial (up to 80 additional patients). Patients with HF, left ventricular ejection fraction (LVEF) ≥50%, and invasive peak exercise pulmonary capillary wedge pressure (PCWP) ≥25 mmHg underwent SAVM. Baseline and follow‐up assessments included resting and exercise PCWP, New York Heart Association (NYHA) class, Kansas City Cardiomyopathy Questionnaire (KCCQ), 6‐min walk test, and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). Efficacy and safety were assessed at 1 and 3 months. Here we report on the first 18 patients with HFpEF that have been enrolled into the roll‐in, open‐label arm of the study across nine centres; 14 (78%) female; 16 (89%) in NYHA class III; and median (interquartile range) age 75.2 (68.4–81) years, LVEF 61.0 (56.0–63.2)%, and average (standard deviation) 20 W exercise PCWP 36.4 (±8.6) mmHg. All 18 patients were successfully treated. Three non‐serious moderate device/procedure‐related adverse events were reported. At 1‐month, the mean PCWP at 20 W exercise decreased from 36.4 (±8.6) to 28.9 (±7.8) mmHg ( p < 0.01), NYHA class improved by at least one class in 33% of patients ( p = 0.02) and KCCQ score improved by 22.1 points (95% confidence interval 9.4–34.2) ( p < 0.01). Conclusion The preliminary open‐label results from the multicentre REBALANCE‐HF roll‐in cohort support the safety and efficacy of SAVM in HFpEF. The findings require confirmation in the ongoing randomized, sham‐controlled portion of the trial.
Non‐steroidal aldosterone receptor antagonism: a ‘fine’ treatment for heart failure patients?
Asleh, Rabea , Briasoulis, Αlexandros , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | May 13, 2022 | Volume: 24 | Issue: 6 | Pages: 1006-1008

10.1002/ejhf.2537 | PMID 35560753 Get It

Abstract 9544: Physical Activity in Individuals With Hypertrophic Cardiomyopathy: Baseline Data From the Prospective "Lifestyle and Exercise in Hcm" (live-hcm) Study
Lampert, Rachel , Ackerman, Michael J. , Marino, Bradley S. , Burg, Matthew M. , Ainsworth, Barbara E. , Balaji, Seshadri , Czosek, Richard J. , Bos, Martijn, Choudhury, Lubna , Etheridge, Susan P. , Ware, James S, Maron, Martin S. , Eidem, Benjamin W., Saarel, Elizabeth V. , Maron, Barry J. , Cannom, David S. , Briske, Kaylie A., Simone, Laura, Barth, Cheryl , Concannon, Maryann, Day, Sharlene M. , Salberg, Lisa , Tome, Maite , Ho, Carolyn Y. , James, Cynthia A. , Emery, Michael S. , Cooper, Robert , Geske, Jeffrey B. , Lal, Ashwin K. , Ware, James S. , Dubin, Anne M. , Gray, Belinda , Molossi, Silvana M , Saberi, Sara , Jacoby, Daniel Louis , Harmon, Kimberly G. , Hall, Kevin D. , Olshansky, Brian , Link, Mark S. , Law, Ian H. , Estes, N.A. Mark , Li, Fangyong

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.9544 Get It

Introduction: Safety of vigorous exercise for individuals with appropriately-treated HCM remains debated. Physical activity practices in this population have not been described. The objective of this report is to describe physical activity pattern in HCM patients. Long term follow up which is ongoing will determine safety of vigorous exercise. Methods: The NIH-funded LIVE-HCM study prospectively enrolled individuals age 8-60 years with clinically overt HCM or patients with a positive genetic test for sarcomeric HCM. Participants (or parents, for children) answered surveys describing activity patterns. Vigorous exercise was defined as > 6 METS for > 60 hours per year. Clinical and demographic data were derived from medical record review. Results: Among 1798 participants, 745 (41%) reported exercising vigorously, including 296 competitive athletes, with 59 at high-school or college varsity level, 770 (43%) were exercising at moderate, and 283 (16%) at low levels. Of those working, 6% described jobs more active than walking, including 16 in protective services, and 11 in sports/coaching. Clinical/demographic data including imaging characteristics and treatments, are shown in Table, and were mostly similar amongst the exercise-groups. Conclusions: Many patients with HCM are engaged in vigorous exercise including competitive athletics. Prospective follow-up of this cohort is ongoing. Comparison of arrhythmic outcomes outcomes in vigorous exercisers vs moderate/low level exercisers will help determine the safety of exercise in HCM patients.
Abstract 8915: Unsupervised Machine Learning Clustering Identifies Low Flow-Low Gradient as High Mortality Risk Phenotypes in Transcatheter Aortic Valve Replacement Patients
Wu, Han-Lun, Rayfield, Corbin, Barry, Timothy , Fatunde, Olubadewa A. , Seri, Amith Reddy , Eleid, Mackram F. , Fortuin, F. David , Sweeney, John P., Pollak, Peter , Sabbagh, Abdallah El , Lester, Steven J., Holmes, David R. , Shen, Win K., Patel, Bhavik N. , Chao, Chieh‐Ju , Agasthi, Pradyumna , Arsanjani, Reza

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.8915 Get It

Introduction: Multiple supervised machine learning (ML) models have been used to assess the outcomes in patients who underwent transcatheter aortic valve replacement (TAVR) procedure, however, supervised ML requires significant expert time for annotation and labeling. Unsupervised ML can provide insight into the dataset without this process. Hypothesis: We hypothesized that unsupervised k-means ML can identify distinct phenogroups in TAVR patients that can predict prognosis without a priori knowledge. Methods: A retrospective study of patients who underwent TAVR (Jan 2012-Dec 2017) at Mayo Clinic sites was performed. Baseline demographics, EKG, cardiac computed tomography, and echocardiographic data were abstracted. Variables with ≥ 20% missing data were excluded. Prior to the k-means clustering algorithm, principal component analysis was used for dimensionality reduction. Input variables were analyzed according to k-means determined clusters. Kaplan-Meier survival analysis was used to assess the survival of each cluster. Results: A total of 1071 consecutive patients were included in the final analysis. A total of 141 unique variables were used. The mean age was 80.7±8.6 years, 58.2% were male. Patients were divided into 2 distinct phenogroups. In the two phenogroups, cluster 0 (n=639) has significantly better survival than cluster 1 (n= 432) (log-rank p=0.0002) (Figure 1). Cluster 1 has features of low flow-low gradient (LFLG) hemodynamic profile, including lower systolic blood pressure, mean aortic valve gradient, peak aortic valve velocity, and worse LV ejection fraction. Conclusions: Unsupervised ML can identify distinct phenotype features with prognostic significance in TAVR patients. Our results suggest that patients with LFLG hemodynamic features are intrinsically different from other TAVR patients and require more attention to avoid adverse outcomes.
Abstract 12158: Higher Body Mass Index is Associated With More Heart Failure-Related Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction
Haase, Christiane L. , Oral, Tuğçe Kalaycı , Varbo, Anette , Morgen, Camilla S. , Schnecke, Volker , Borlaug, Barry A.

Mayo Clinic

Circulation | April 28, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.12158 Get It

Introduction: In people with heart failure (HF) with preserved ejection fraction (HFpEF), the associations between BMI, comorbidities and outcomes are not well-defined. This retrospective cohort study examined the association between BMI and hospitalizations in patients with HFpEF. Hypothesis: Higher BMI is associated with more HF-related hospitalizations and shorter time to HF-related hospitalization. Methods: Data for patients with BMI ≥25 kg/m 2 at the time of HFpEF diagnosis were extracted from LCED, a US claims-electronic medical record data set. Patients were categorized into 5 BMI groups: overweight and obesity classes I-IV (Figure A). Negative binomial and Cox proportional hazard models were used to estimate associations between BMI and number of HF-related hospitalizations and risk of HF-related hospitalization during follow-up. Analyses were adjusted for relevant baseline comorbidities, with age, sex and diabetes status as effect modifiers. Results: Among 4,975 patients, median age was 74 years and 57.5% were female. Compared with the overweight group, higher BMI groups had a lower median age (years: overweight 80; obesity III 68; obesity IV 64), fewer patients with cardiovascular (CV) history (overweight 81.0%; obesity III 77.0%; obesity IV 66.0%) and a greater proportion of female patients (overweight 56.4%; obesity III 57.9%; obesity IV 69.0%) (Figure A). Mean HF-related hospitalizations/100 patient-years was higher for obesity III (12) and IV (16) vs overweight (10) (effect of BMI: p=0.002; Figure B). The hazard ratio [95% CI] for HF-related hospitalization was 1.36 [0.97; 1.91] and 1.86 [1.32; 2.64] for obesity III and IV, relative to overweight (effect of BMI: p=0.010). Conclusions: Results suggest even though patients with HFpEF in higher BMI groups are younger and have less CV history at baseline, higher BMI is associated with greater burden of HF-related hospitalizations during follow-up, irrespective of age, sex and diabetes status.
Unloading the right to fill the left: vasodilation to treat hypotension: a case report
Ezzeddine, Fatima M. , Bois, Melanie C. , Borlaug, Barry A. , Borlaug, Barry A , Ezzeddine, Fatima

Mayo Clinic

European Heart Journal - Case Reports | April 23, 2022 | Volume: 6 | Issue: 6 | Pages: No page available

10.1093/ehjcr/ytac179 | PMID 35668846 Get It

Abstract Background Management of pulmonary hypertension (PH) in the setting of heart failure with preserved ejection fraction (HFpEF) can be challenging. Herein, we describe the case of a patient with HFpEF and combined pre- and post-capillary PH who showed striking improvement with sildenafil. Case summary A 74-year-old man presented with exertional dyspnea and near-syncope. He underwent a hemodynamic exercise study that showed evidence of HFpEF with pre- and post-capillary PH. Right ventricular endomyocardial biopsy showed interstitial fibrosis and mild hypertrophy, with no evidence of infiltrative or storage diseases. The patient was treated with sildenafil 20 mg three times daily, which resulted in significant symptomatic and functional improvement in 12 years of follow-up. Discussion Phosphodiesterase 5 inhibitors are currently not approved by the United States Food and Drug Administration for treatment of PH in heart failure and are used off-label in patients with heart failure. This case illustrates the importance of unloading the right ventricle to improve cardiac output in patients with diastolic dysfunction and combined pre- and post-capillary PH. Although promising, future studies are needed to validate these findings.
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
Li, Maggie , Beck, Evan J. , Laeyendecker, Oliver , Eby, Yolanda , Wouters, Camille, Chiklis, Gregory R., Block, William , McKie, Robert O., Joyner, Michael J. , Wiltshire, Timothy D. , Dietz, Allan B. , Gniadek, Thomas J. , Shapiro, Arell, Yarava, Anusha , Lane, Karen , Bloch, Evan M. , Cachay, Edward R. , Huamán, Moisés A. , Fukuta, Yuriko , Patel, Bela , Heath, Sonya L. , Gerber, Jonathan M. , Sullivan, David , Wiltshire, Timothy D , Dietz, Allan B , Hanley, Daniel F , Bloch, Evan M , Shoham, Shmuel , Cachay, Edward R , Huaman, Moises A , Levine, Adam C , Paxton, James H , Gerber, Jonathan M , Gebo, Kelly A , Casadevall, Arturo , Sullivan, David J , Joyner, Michael J , Laeyendecker, Oliver , Tobian, Aaron A.R. , Caturegli, Patrizio , Block, William, Hanley, Daniel F. , Shoham, Shmuel , Meisenberg, Barry R. , Anjan, Shweta , Casadevall, Arturo , Pekosz, Andrew

Mayo Clinic

Blood Advances | April 20, 2022 | Volume: 6 | Issue: 12 | Pages: 3678-3683

10.1182/bloodadvances.2022007410 | PMID 35443020 Get It

Abstract The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-δ/pre-ο donor units obtained before March 2021, 20 post-δ COVID-19/postvaccination units, and 1 pre-δ/pre-ο hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], δ, and ο) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to δ or ο, respectively. CCP antibody levels in the upper 10% of the 108 donations as well as 100% of the post-δ COVID-19/postvaccination units and the hyperimmunoglobulin effectively neutralized all 3 variants. High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants.
Heart failure with normal natriuretic peptide levels: more fat, and that is the main problem
Verbrugge, Frederik H. , Borlaug, Barry A. , Borlaug, Barry A , Verbrugge, Frederik H

Mayo Clinic

European Heart Journal | April 14, 2022 | Volume: 43 | Issue: 23 | Pages: 2248-2249

10.1093/eurheartj/ehac194 | PMID 35441667 Get It

Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential
Nakao, Tetsushi , Bick, Alexander G. , Taub, Margaret A. , Uddin, Md Mesbah , Niroula, Abhishek , Carty, Cara L. , Lane, John , Honigberg, Michael C. , Weinstock, Joshua S. , Pampana, Akhil , Griffin, Gabriel K. , Bhattacharya, Romit , Assimes, Themistocles L. , Emery, Leslie S. , Wong, Quenna , Broome, Jai , Laurie, Cecelia , Khan, Alyna , Smith, Albert V. , Blackwell, Thomas W. , Nelson, Christopher P. , Yoneda, Zachary T. , Peralta, Juan M. , Bowden, Donald W. , Irvin, Marguerite R. , Boorgula, Meher Preethi, Zhao, Wei , Yanek, Lisa R. , Roden, Dan M. , Reupena, Muagututi‘a Sefuiva , DeMeo, Dawn L. , Kelly, Shannon , Musani, Solomon K., Bis, Joshua C. , Lloyd‐Jones, Donald M. , Peyser, Patricia A. , Qiao, Dandi , Tiwari, Hemant K., Smith, Jennifer A. , Smith, Nicholas L. , Kelly, Tanika N. , Hidalgo, Bertha , Weeks, Daniel E. , Group, The Samoan Obesity, Lifestyle and Genetic Adaptations Study (OLaGA), Deka, Ranjan , Naseri, Take, Fuentes, Lisa de las , Raffield, Laura M. , Morrison, Alanna C. , Vries, Paul S. de , Shoemaker, M. Benjamin , Palmer, Nicholette D. , Barnes, Kathleen C. , Redline, Susan , Kardia, Sharon L.R., Becker, Lewis C. , Heckbert, Susan R. , He, Jiang , Post, Wendy S. , Arnett, Donna K. , McGarvey, Stephen T. , Chen, Yii‐Der Ida , Kaplan, Robert C. , Meyers, Deborah A. , Fornage, Myriam , Boerwinkle, Eric , Loos, Ruth J. F. , Silverman, Edwin K. , Danesh, John , Samani, Nilesh J. , Jaiswal, Siddhartha , Ebert, Benjamin L. , Reiner, Alex P. , Mathias, Rasika A. , Do, Ron , Natarajan, Pradeep , Zhao, Wei , Zekavat, Seyedeh M , Uddin, Md M , Niroula, Abhishek , Lane, John , Honigberg, Michael C , Weinstock, Joshua S , Pampana, Akhil , Griffin, Gabriel K , Clarke, Shoa L , Bhattacharya, Romit , Assimes, Themistocles L , Emery, Leslie S , Stilp, Adrienne M , Wong, Quenna , Broome, Jai , Khan, Alyna T , Smith, Albert V , Codd, Veryan , Nelson, Christopher P , Yoneda, Zachary T , Peralta, Juan M , Yanek, Lisa R , Wiggins, Kerri L , Gu, C Charles , Peloso, Gina M , Roden, Dan M. , Hwu, Chii-Min , North, Kari E. , Bis, Joshua C , Lloyd-Jones, Donald M , Johnsen, Jill M , Preuss, Michael , Tracy, Russell P , Peyser, Patricia A , Qiao, Dandi , Curran, Joanne E , Freedman, Barry I , Chavan, Sameer , Smith, Jennifer A , Kelly, Tanika N , Hidalgo, Bertha , Weeks, Daniel E , Hawley, Nicola L , Minster, Ryan L , de las Fuentes, Lisa , Raffield, Laura M , Ballantyne, Christie M , Kenny, Eimear E , Rich, Stephen S , Whitsel, Eric A , Cho, Michael H , Palmer, Nicholette D , Mitchell, Braxton D , Shuldiner, Alan R , Redline, Susan , Heckbert, Susan R , He, Jiang , Post, Wendy , Arnett, Donna K , Vasan, Ramachandran S , Weiss, Scott T , McGarvey, Stephen T , Custer, Brian S , Correa, Adolfo , Manson, JoAnn E , Konkle, Barbara A , Loos, Ruth J F , Rotter, Jerome I , Silverman, Edwin K , Kooperberg, Charles , Samani, Nilesh J , Jaiswal, Siddhartha , Libby, Peter , Ellinor, Patrick T , Pankratz, Nathan , Ebert, Benjamin L , Mathias, Rasika A , Do, Ron , Natarajan, Pradeep , Morrison, Alanna C , Bick, Alexander G , Gibson, Christopher James , Clarke, Shoa L. , Codd, Veryan , Wiggins, Kerri L. , Hixson, James E. , Peloso, Gina M. , Tracy, Russell P. , Desai, Pinkal , Curran, Joanne E. , Freedman, Barry I. , Cupples, L. Adrienne , Group, The Samoan Obesity, Lifestyle and Genetic Adaptations Study (OLaGA), Naseri, Take K. , Ballantyne, Christie M. , Rich, Stephen S. , Cho, Michael H. , Pace, Betty S. , Blangero, John , Mitchell, Braxton D. , Shuldiner, Alan R. , Abecasis, Gonçalo R. , Vasan, Ramachandran S. , Darbar, Dawood , Weiss, Scott T. , Andrade, Mariza de , Custer, Brian , Psaty, Bruce M. , Manson, JoAnn E. , Konkle, Barbara A. , Rotter, Jerome I. , Kooperberg, Charles , Libby, Peter , Ellinor, Patrick T. , Pankratz, Nathan

Mayo Clinic

Science Advances | April 6, 2022 | Volume: 8 | Issue: 14 | Pages: No page available

10.1126/sciadv.abl6579 | PMID 35385311 Get It

Human genetic studies support an inverse causal relationship between leukocyte telomere length (LTL) and coronary artery disease (CAD), but directionally mixed effects for LTL and diverse malignancies. Clonal hematopoiesis of indeterminate potential (CHIP), characterized by expansion of hematopoietic cells bearing leukemogenic mutations, predisposes both hematologic malignancy and CAD. TERT (which encodes telomerase reverse transcriptase) is the most significantly associated germline locus for CHIP in genome-wide association studies. Here, we investigated the relationship between CHIP, LTL, and CAD in the Trans-Omics for Precision Medicine (TOPMed) program ( n = 63,302) and UK Biobank ( n = 47,080). Bidirectional Mendelian randomization studies were consistent with longer genetically imputed LTL increasing propensity to develop CHIP, but CHIP then, in turn, hastens to shorten measured LTL (mLTL). We also demonstrated evidence of modest mediation between CHIP and CAD by mLTL. Our data promote an understanding of potential causal relationships across CHIP and LTL toward prevention of CAD.
Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX
Shropshire, William C. , Dinh, An Q , Earley, Michelle, Komarow, Lauren , Panesso, Diana , Rydell, Kirsten, Gómez-Villegas, Sara I, Miao, Hongyu , Hill, Carol , Chen, Liang , Patel, Robin , Abbo, Lilian M. , Cober, Eric , Revolinski, Sara , Luterbach, Courtney , Chambers, Henry F. , Fowler, Vance G. , Shelburne, Samuel A. , Kreiswirth, Barry N. , Hanson, Blake , Arias, César A. , Revolinski, Sara , Bonomo, Robert A , Shelburne, Samuel A , Kreiswirth, Barry N , van Duin, David , Hanson, Blake M , Chen, Liang , Patel, Robin , Abbo, Lilian M , Fries, Bettina C. , Fowler, Vance G. , Bonomo, Robert A. , Arias, César A.

Mayo Clinic

mBio | March 31, 2022 | Volume: 13 | Issue: 2 | Pages: No page available

10.1128/mbio.00497-22 | PMID 35357213 Get It

The prevalence of carbapenem-resistant Klebsiella pneumoniae (CR Kp ) infections in nosocomial settings remains a public health challenge. High-risk clones such as clonal group 258 (CG258) are particularly concerning due to their association with bla KPC carriage, which can severely complicate antimicrobial treatments.